Track topics on Twitter Track topics that are important to you
New report says adding a BAP1 test to a 10-biomarker panel increased diagnostic accuracy for pleural mesothelioma to 93 percent.
RALEIGH, N.C. (PRWEB) October 25, 2017
Researchers at China’s Zhejiang Cancer Hospital say their evaluation of people with pleural mesothelioma or non-small cell lung cancer shows BAP1 is a valuable way to tell the difference. Surviving Mesothelioma has the full story. Click here to read the article now.
“All 80 cases of non-small cell lung cancer and 15 cases of carcinosarcoma were BAP1 positive,” writes lead investigator ZY Guo. “In contrast, 64 percent (14/22) of malignant mesotheliomas lost BAP1 expression.”
The report in the Chinese Journal of Pathology suggests that BAP1 testing can not only help distinguish pleural mesothelioma from other types of cancer, but can be used to improve diagnostic accuracy and facilitate earlier treatment.
“We know that mesothelioma survival is closely linked to early and accurate diagnosis,” says Alex Strauss, Managing Editor for Surviving Mesothelioma. “If BAP1 testing can improve diagnostic accuracy for this hard-to-diagnose cancer, it also has the potential to improve pleural mesothelioma outcomes.”
A summary of the study’s findings is now available on the Surviving Mesothelioma website in an article titled BAP1 Test Offers More Accurate Mesothelioma Diagnosis.
Guo, ZY, “Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application”, October 8, 2017, Chinese Journal of Pathology, https://www.ncbi.nlm.nih.gov/pubmed/29050072
For more than a decade, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.
For the original version on PRWeb visit: http://www.prweb.com/releases/2017/10/prweb14841642.htmNEXT ARTICLE
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...